1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
AbbVie Inc.

AbbVie Inc.

ABBV
AbbVie Inc.US flagNew York Stock Exchange
257.06
USD
+2.06
- -
454.17BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
11.84
12.54
14.2
16.1
17.72
22.15
22.49
25.95
31.78
32.81
30.76
31.91
34.6
36.43
Basic EPS, GAAP
2.6
1.11
3.2
3.74
3.33
3.85
5.33
2.62
6.53
6.69
2.75
2.42
2.39
3.57
Free Cash Flow per Basic Share
3.64
1.85
4.35
4.12
5.92
8.65
8.64
9.51
12.44
13.71
12.49
10.1
10.08
10.3
Dividend per Share
1.61
1.67
2.05
2.33
2.58
3.77
4.3
4.37
5.24
5.68
5.97
6.25
6.59
6.78
Book Value per Share
2.83
1.09
2.45
2.91
3.2
-5.71
-5.53
7.41
8.71
9.75
5.87
1.88
-1.85
-3.36
Tangible Book Value per Share
-2.32
-3.54
-17.97
-24.91
-24.02
-30.66
-28.69
-58.31
-52.55
-46.54
-43.91
-51.95
-51.79
-51.27
Basic Weighted Avg Shares
1,587
1,591
1,610
1,593
1,592
1,479
1,479
1,765
1,768
1,769
1,766
1,765
1,768
1,767
Sales/Revenue/Turnover
18,790
19,960
22,859
25,638
28,216
32,753
33,266
45,804
56,197
58,054
54,318
56,334
61,160
64,386
Operating Margin (%)
30.14
17.09
32.97
36.43
33.83
19.49
39.03
24.81
31.89
32.41
24.92
21.11
32.85
33.94
Depreciation Expense
897
786
836
1,189
1,501
1,765
2,017
6,471
8,521
8,467
8,698
8,386
8,139
7,869
Net Income, GAAP
4,128
1,774
5,144
5,953
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
6,310
Effective Tax Rate (%)
22.58
25.12
22.59
24.49
31.29
- -
6.46
- -
11.09
12.11
22.03
- -
35.83
27.39
Profit Margin (%)
21.97
8.89
22.5
23.22
18.82
17.36
23.69
10.08
20.54
20.39
8.95
7.59
6.91
9.8
Working Capital
10,969
4,688
5,420
6,406
4,582
-294
33,934
-4,488
-7,266
-1,075
-4,839
-13,167
-14,227
-7,973
LT Debt
14,292
10,538
29,240
36,440
30,953
35,002
62,975
77,554
64,189
59,135
52,194
60,340
58,941
62,481
Total Equity
4,492
1,742
3,945
4,636
5,097
-8,446
-8,172
13,097
15,436
17,287
10,397
3,364
-3,228
-5,888
Return on Invested Capital (%)
22.93
14.22
22.3
18.3
15.63
- -
26.89
- -
16.66
19.15
14.04
- -
19.13
23.45
Return on Capital (%)
22.79
11.66
21.78
17.49
14.53
- -
21.13
- -
14.31
15.97
8.76
- -
9.02
12.45
Return on Common Equity (%)
105.11
56.91
180.9
138.75
109.09
128.33
194.11
158.95
81.04
72.48
35.22
62.52
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,555
8,326
8,341
LT Borrowings
58,941
64,532
62,481
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,768
1,767
1,767
Market Capitalization
403,942
384,247
444,665

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
29,062
33,529
33,669
Cash, Cash Equivalents & STI
5,257
9,391
6,569
Accounts Receivable, Net
12,589
12,479
13,824
Inventories
4,951
5,049
5,127
Total Current Liabilities
43,289
42,100
41,642
Payables & Accruals
34,734
33,774
33,301
ST Debt
8,555
8,326
8,341
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-77.54%
-54.72%
-195.96%
Free Cash Flow
11.73%
2.59%
-0.09%
Net Income, GAAP
8.96%
16.09%
-1.22%
Sales/Revenue/Turnover
10.94%
6.37%
8.57%
Total Cash Common Dividend
13.82%
8.75%
5.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,310
14,462
14,460
15,102
56,334
2025
13,343
15,423
15,776
16,618
61,160
2026
15,002
16,990
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.78
0.78
0.88
-0.01
2.42
2025
0.73
0.53
0.11
1.03
2.39
2026
0.39
2.04
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.57
1.56
1.56
1.56
6.25
2025
1.66
1.65
1.65
1.65
6.59
2026
1.75
1.74
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Robert A. Michael
Full Time Employees
57,000
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
1 North Waukegan Road North Chicago IL United States of America 60064-6400
IPO Date
Jan 2, 2013
CIK
0001551152
Website
abbvie.com
Similar Companies
Roche Holding AG (ROG.SW)
AbbVie Inc. (ABBV.BA)
Astellas Pharma Inc. (ALPMF)
Senores Pharmaceuticals Ltd. (SENORES.NS)
Gilead Sciences, Inc. (GIS.DE)
Orion Oyj (ORINY)
Business
AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.

Company News

Company News APIChatGPT

  • 247wallst.com

    How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?

  • defenseworld.net

    Advisory Solutions Group LLC Invests $839,000 in AbbVie Inc. $ABBV

  • defenseworld.net

    Angeles Wealth Management LLC Has $5.90 Million Position in AbbVie Inc. $ABBV

  • defenseworld.net

    10,631 Shares in AbbVie Inc. $ABBV Bought by Markowski Investments

  • defenseworld.net

    NBH Bank Takes $1.81 Million Position in AbbVie Inc. $ABBV

  • defenseworld.net

    3,893 Shares in AbbVie Inc. $ABBV Bought by Maloon Powers Pitre Higgins & Dennehy LLC

  • defenseworld.net

    MW Advisory LLC Acquires New Stake in AbbVie Inc. $ABBV

  • fool.com

    Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?

  • zacks.com

    AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study

  • benzinga.com

    What's Going On With AbbVie Stock Friday?

  • 247wallst.com

    How Much Dividend Income Can You Buy With $250,000?

  • fool.com

    Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

  • prnewswire.com

    AbbVie Declares Quarterly Dividend

  • fool.com

    AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

  • zacks.com

    AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

  • seekingalpha.com

    ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie

  • reuters.com

    AbbVie's migraine treatment meets late-stage study goal

  • prnewswire.com

    AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

  • fool.com

    Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?

  • fool.com

    Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?